{ "instance": { "grna-20220331.htm": { "axisCustom": 3, "axisStandard": 28, "contextCount": 283, "dts": { "calculationLink": { "local": [ "grna-20220331_cal.xml" ] }, "definitionLink": { "local": [ "grna-20220331_def.xml" ] }, "inline": { "local": [ "grna-20220331.htm" ] }, "labelLink": { "local": [ "grna-20220331_lab.xml" ] }, "presentationLink": { "local": [ "grna-20220331_pre.xml" ] }, "schema": { "local": [ "grna-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 682, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 8, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 12 }, "keyCustom": 101, "keyStandard": 297, "memberCustom": 55, "memberStandard": 32, "nsprefix": "grna", "nsuri": "http://greenlightbiosciences.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Summary of Significant Accounting Policies", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Business Combination", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - License Agreement", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "shortName": "License Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAndCollaborationAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - License and Collaboration Agreements", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAndCollaborationAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Fair Value Measurements", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:GrantRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Grant Revenue", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "shortName": "Grant Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:GrantRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Property and Equipment, Net", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Accrued Expenses", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:AccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Debt", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Warrants", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stockholders' Equity", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Stock-Based Compensation", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Net Loss Per Share", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Income Taxes", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Commitments and Contingencies", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Subsequent Events", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "grna:ScheduleOfConsolidatedStatementOfOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Nature of Business and Basis of Presentation (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationTables", "shortName": "Nature of Business and Basis of Presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "grna:ScheduleOfConsolidatedStatementOfOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Business Combination (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Fair Value Measurements (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "grna:AccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:AccruedLiabilitiesDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Accrued Expenses (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "grna:AccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:AccruedLiabilitiesDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Debt (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:SummaryOfRollForwardOfWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Warrants (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "grna:SummaryOfRollForwardOfWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stockholder's Equity (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholder's Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Net Loss Per Share (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Nature of Business and Basis of Presentation (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "shortName": "Nature of Business and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_a9162278-3a50-4495-ac3c-46764155897e", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Nature of Business and Basis of Presentation - Schedule of Restatement Consolidated Statement of Operations (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "shortName": "Nature of Business and Basis of Presentation - Schedule of Restatement Consolidated Statement of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_3f85a3ab-e79a-424b-a32d-60d50f7db467", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Nature of Business and Basis of Presentation - Schedule Of Restatement Earnings Per Share Basic And Diluted (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "shortName": "Nature of Business and Basis of Presentation - Schedule Of Restatement Earnings Per Share Basic And Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_8c619060-2d88-4942-bd48-426c0e055eeb", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-5", "lang": null, "name": "grna:DeferredOfferingCostsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_9cf2512e-4fc0-45c9-8574-0d0ed35b1d7c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_9cf2512e-4fc0-45c9-8574-0d0ed35b1d7c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5abecd68-275d-4923-9653-92bc546416a1", "decimals": "INF", "first": true, "lang": null, "name": "grna:AuthorizedSharesCapital", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Business Combination - Additional Information (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "shortName": "Business Combination - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5abecd68-275d-4923-9653-92bc546416a1", "decimals": "INF", "first": true, "lang": null, "name": "grna:AuthorizedSharesCapital", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c18d6e20-02dc-4d28-9d6b-a13cee05e7bb", "decimals": "-3", "first": true, "lang": null, "name": "grna:BusinessCombinationGrossProceeds", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Business Combination - Summary of Reconciles Elements of Business Combination (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails", "shortName": "Business Combination - Summary of Reconciles Elements of Business Combination (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c18d6e20-02dc-4d28-9d6b-a13cee05e7bb", "decimals": "-3", "first": true, "lang": null, "name": "grna:BusinessCombinationGrossProceeds", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "grna:ScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5abecd68-275d-4923-9653-92bc546416a1", "decimals": "INF", "first": true, "lang": null, "name": "grna:CommonStockSharesOutstandingPriorToBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Consummation of Business Combination (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "shortName": "Business Combination - Schedule of Number of Shares of Common Stock Outstanding Immediately Consummation of Business Combination (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "grna:ScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5abecd68-275d-4923-9653-92bc546416a1", "decimals": "INF", "first": true, "lang": null, "name": "grna:CommonStockSharesOutstandingPriorToBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "grna:LicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5a34c5b7-a302-486c-a4a1-aa0ed1bb008e", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - License Agreement - Additional Information (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "shortName": "License Agreement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "grna:LicenseAgreementTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5a34c5b7-a302-486c-a4a1-aa0ed1bb008e", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "grna:LicenseAndCollaborationAgreementsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_8f32e7a0-7518-4873-92f6-20df814a6ef0", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAgreementDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "grna:LicenseAndCollaborationAgreementsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_8f32e7a0-7518-4873-92f6-20df814a6ef0", "decimals": null, "first": true, "lang": "en-US", "name": "grna:LicenseAgreementDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_21cde926-c0fc-4f32-8cea-d229e6197429", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis", "shortName": "Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_21cde926-c0fc-4f32-8cea-d229e6197429", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_17785e5e-d81e-41b3-9cab-44b61bb37116", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_17785e5e-d81e-41b3-9cab-44b61bb37116", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Fair Value Measurements (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-5", "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_31ebf39f-7147-4211-8111-9af081366410", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities", "shortName": "Fair Value Measurements (Details) - Schedule of changes in the fair value of Level 3 warrant liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_31ebf39f-7147-4211-8111-9af081366410", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Grant Revenue - Additional Information (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "shortName": "Grant Revenue - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "grna:GrantRevenueTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_1f812e14-fa5a-4d35-988d-1c3ffcf79486", "decimals": "-5", "lang": null, "name": "grna:GrantReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Property and Equipment, Net - Additional Information (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "shortName": "Property and Equipment, Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "grna:AccruedLiabilitiesDisclosureTableTextBlock", "div", "grna:AccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-3", "first": true, "lang": null, "name": "grna:ConvertibleNotesPayableUnamortizedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Debt - Summary of Outstanding Debt (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "shortName": "Debt - Summary of Outstanding Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-3", "first": true, "lang": null, "name": "grna:ConvertibleNotesPayableUnamortizedDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_2c825b9e-467b-4422-b8b1-f1eb5e4602fd", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Debt - Summary of Outstanding Debt (Parenthetical) (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails", "shortName": "Debt - Summary of Outstanding Debt (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_be84a78f-988b-466f-8a46-5abdf54930ae", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Debt - Additional Information (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": "3", "lang": null, "name": "grna:DebtInstrumentFinalPaymentFeeChargedAsPercentageOfPrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Debt - Summary Of Interest Expense (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail", "shortName": "Debt - Summary Of Interest Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals) (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Debt - Summary Of Future Principal Payment Of Long Term Debt (Detail)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail", "shortName": "Debt - Summary Of Future Principal Payment Of Long Term Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_626342de-dc5a-4369-a888-5cc85d5a5bc1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Warrants - Additional Information (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "shortName": "Warrants - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_e5cea615-5689-41cf-9309-f697a92c6549", "decimals": "0", "lang": null, "name": "grna:PublicWarrantsExercises", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5dae1dea-a6e3-425d-b0ad-6c3550a0beeb", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Warrants - Summary of Common Stock Warrant Classified (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "shortName": "Warrants - Summary of Common Stock Warrant Classified (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_e5e7328a-0c32-4e6c-8997-695557ee56e3", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_e0583082-18e9-4336-9eba-38f28a826d7a", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Warrants - Summary of Estimated Fair Value of the Warrants (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "shortName": "Warrants - Summary of Estimated Fair Value of the Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_e0583082-18e9-4336-9eba-38f28a826d7a", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "grna:SummaryOfRollForwardOfWarrantsTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_3d20d955-85cd-47c6-9a8b-268988b98d28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Warrants - Summary of Roll-forward of the Warrants (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails", "shortName": "Warrants - Summary of Roll-forward of the Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "grna:SummaryOfRollForwardOfWarrantsTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_671a40f2-bb6b-42c7-b387-eaaf2b7a963a", "decimals": "0", "lang": null, "name": "grna:BusinessCombinationWarrantsExercised", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c18d6e20-02dc-4d28-9d6b-a13cee05e7bb", "decimals": "3", "first": true, "lang": null, "name": "grna:BusinessCombinationsExchangeRatio", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Warrants - Summary of Roll-forward of the Warrants (Parenthetical) (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsParentheticalDetails", "shortName": "Warrants - Summary of Roll-forward of the Warrants (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_5abecd68-275d-4923-9653-92bc546416a1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": null, "lang": "en-US", "name": "grna:TemporaryEquityVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_72000bca-f0ab-476d-b958-b4f51ae69cf3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "shortName": "Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_72000bca-f0ab-476d-b958-b4f51ae69cf3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d4688561-cd91-426b-9146-fb8800653642", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Parenthetical) (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "shortName": "Stockholders' Equity - Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d4688561-cd91-426b-9146-fb8800653642", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Stock-Based Compensation - Additional information (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100100 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_ba9315d3-7c46-4634-ac34-b717aed75f27", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Stock-Based Compensation - Summary of Fair Value Assumptions of Stock Option Awards Estimated on Grant Date (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "shortName": "Stock-Based Compensation - Summary of Fair Value Assumptions of Stock Option Awards Estimated on Grant Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_ba9315d3-7c46-4634-ac34-b717aed75f27", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_42a4a235-a76a-4d1d-b3dd-b327098b1597", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_fbadb79d-78a9-443f-b557-eaf1437441bc", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c18d6e20-02dc-4d28-9d6b-a13cee05e7bb", "decimals": "3", "first": true, "lang": null, "name": "grna:BusinessCombinationsExchangeRatio", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityParentheticalDetails", "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_4df6c66f-6309-4c53-94c9-8c1b53619d9f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_4df6c66f-6309-4c53-94c9-8c1b53619d9f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Net Loss Per Share - Summary of the computation of basic and diluted net loss per share attributable to common stockholders (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss Per Share - Summary of the computation of basic and diluted net loss per share attributable to common stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Net Loss Per Share - Summary of the excluded potential common stock (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails", "shortName": "Net Loss Per Share - Summary of the excluded potential common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_c7d1fd7b-7849-422d-98af-e739ff750e4a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Income Taxes (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_fcc37539-2369-4541-b811-a91b64276212", "decimals": "INF", "first": true, "lang": null, "name": "grna:MilestonePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Commitments and Contingencies (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_fcc37539-2369-4541-b811-a91b64276212", "decimals": "INF", "first": true, "lang": null, "name": "grna:MilestonePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Commitments and Contingencies - Summary of future minimum lease payments under noncancelable operating leases (Details)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails", "shortName": "Commitments and Contingencies - Summary of future minimum lease payments under noncancelable operating leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_60da2ddc-4715-4bbe-88b1-63af04c33daa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_d6def628-3d46-42e2-936c-de8b7b4706e1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100110 - Statement - Consolidated Statements of Cash Flows (Parenthetical) (Unaudited)", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited", "shortName": "Consolidated Statements of Cash Flows (Parenthetical) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Nature of Business and Basis of Presentation", "role": "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "shortName": "Nature of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "grna-20220331.htm", "contextRef": "C_da0852ba-9ab7-479e-a703-e9f46df057ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 92, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "grna_AccountingPoliciesByPolicyPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting policies, by Policy (policies).", "label": "Accounting Policies, by Policy (Policies) [Line Items]" } } }, "localname": "AccountingPoliciesByPolicyPoliciesLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "stringItemType" }, "grna_AccruedLiabilitiesCurrentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Line Items]" } } }, "localname": "AccruedLiabilitiesCurrentLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables" ], "xbrltype": "stringItemType" }, "grna_AccruedLiabilitiesCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Table]" } } }, "localname": "AccruedLiabilitiesCurrentTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables" ], "xbrltype": "stringItemType" }, "grna_AccruedLiabilitiesDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities Disclosure", "label": "Accrued Liabilities Disclosure [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "grna_AccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued liabilities disclosure.", "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "grna_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development", "label": "Accrued Research and Development Current", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "grna_AcuitasTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acuitas therapeutics inc.", "label": "Acuitas Therapeutics Inc [Member]" } } }, "localname": "AcuitasTherapeuticsIncMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_AdjustmentsToAdditionalPaidInCapitalExerciseOfConvertiblePreferredStockWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital exercise of convertible preferred stock warrant.", "label": "Adjustments To Additional Paid in Capital Exercise of Convertible Preferred Stock Warrant", "terseLabel": "Cashless exercise of Legacy GreenLight preferred stock warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfConvertiblePreferredStockWarrant", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid-in capital reclassification of warrants to equity.", "label": "Adjustments To Additional Paid In Capital Reclassification of Warrants to Equity", "terseLabel": "Reclassification of Legacy GreenLight common stock warrants to equity" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_AggregateGrantReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate grant received", "label": "Aggregate Grant Received", "terseLabel": "Aggregate grant received" } } }, "localname": "AggregateGrantReceived", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_AnnualLicenseMaintenanceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual license maintenance fee.", "label": "Annual License Maintenance Fee", "verboseLabel": "Annual license maintenance fee" } } }, "localname": "AnnualLicenseMaintenanceFee", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_AuthorizedSharesCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized shares capital.", "label": "Authorized Shares Capital", "terseLabel": "Authorized shares capital" } } }, "localname": "AuthorizedSharesCapital", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "grna_BayerCropscienceLlpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer CropScience LLP.", "label": "Bayer CropScience LLP [Member]" } } }, "localname": "BayerCropscienceLlpMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "grna_BillAndMelindaGatesFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bill and Melinda Gates Foundation [Member]" } } }, "localname": "BillAndMelindaGatesFoundationMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_BusinessCombinationAccruedTransactionCosts": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 5.0, "parentTag": "grna_ReverseMergerNetOfTransactionsCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination accrued transaction costs.", "label": "Business Combination Accrued Transaction Costs", "negatedLabel": "Less: transaction costs accrued at March 31, 2022" } } }, "localname": "BusinessCombinationAccruedTransactionCosts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_BusinessCombinationExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination exchange ratio.", "label": "Business Combination Exchange Ratio", "terseLabel": "Business combination exchange ratio" } } }, "localname": "BusinessCombinationExchangeRatio", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsParentheticalDetails" ], "xbrltype": "percentItemType" }, "grna_BusinessCombinationGrossProceeds": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 0.0, "parentTag": "grna_CashProceedsFromBusinessCombination", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination gross proceeds", "label": "Business Combination Gross Proceeds", "terseLabel": "Gross Proceeds", "totalLabel": "Gross Proceeds" } } }, "localname": "BusinessCombinationGrossProceeds", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BusinessCombinationMember", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "grna_BusinessCombinationTransactionCostsAccrued": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 4.0, "parentTag": "grna_CashProceedsFromBusinessCombination", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination transaction costs accrued.", "label": "Business Combination Transaction Costs Accrued", "terseLabel": "Add: transaction costs accrued at March 31. 2022" } } }, "localname": "BusinessCombinationTransactionCostsAccrued", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_BusinessCombinationTransactionCostsAndPaidInTwoThousandTwentyOne": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 3.0, "parentTag": "grna_CashProceedsFromBusinessCombination", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination transaction costs and paid in two thousand twenty one.", "label": "Business Combination Transaction Costs And Paid In Two Thousand Twenty One", "terseLabel": "Add: transaction costs paid in 2021" } } }, "localname": "BusinessCombinationTransactionCostsAndPaidInTwoThousandTwentyOne", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_BusinessCombinationTransactionCostsPaid": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 1.0, "parentTag": "grna_CashProceedsFromBusinessCombination", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination transaction costs paid.", "label": "Business Combination Transaction Costs Paid", "negatedLabel": "Less: total transaction costs" } } }, "localname": "BusinessCombinationTransactionCostsPaid", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_BusinessCombinationWarrantsAssumed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination warrants assumed.", "label": "Business Combination Warrants Assumed", "terseLabel": "Assumed in the business combination" } } }, "localname": "BusinessCombinationWarrantsAssumed", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "sharesItemType" }, "grna_BusinessCombinationWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination warrants exercised.", "label": "Business Combination Warrants Exercised", "terseLabel": "Exercised in the business combination" } } }, "localname": "BusinessCombinationWarrantsExercised", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "sharesItemType" }, "grna_BusinessCombinationsExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combinations exchange ratio.", "label": "Business Combinations Exchange Ratio", "terseLabel": "Business combination exchange ratio" } } }, "localname": "BusinessCombinationsExchangeRatio", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsParentheticalDetails" ], "xbrltype": "pureItemType" }, "grna_CapitalLeaseObligationsGross": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail3": { "order": 0.0, "parentTag": "us-gaap_CapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital lease obligations gross.", "label": "Capital Lease Obligations Gross", "terseLabel": "Capital lease, Principle Balance" } } }, "localname": "CapitalLeaseObligationsGross", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "grna_CashAcquiredNetOfRedemption": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 0.0, "parentTag": "grna_BusinessCombinationGrossProceeds", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash acquired net of redemption.", "label": "Cash Acquired Net of Redemption", "terseLabel": "Cash (net of redemption)", "verboseLabel": "Purchase price" } } }, "localname": "CashAcquiredNetOfRedemption", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "grna_CashProceedsFromBusinessCombination": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 0.0, "parentTag": "grna_ReverseMergerNetOfTransactionsCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash proceeds from business combination.", "label": "Cash Proceeds from Business Combination", "terseLabel": "Cash Proceeds from Business Combination - received in 2022", "totalLabel": "Cash proceeds from Business Combination received in 2022" } } }, "localname": "CashProceedsFromBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_CashProceedsFromConvertibleNotes": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 2.0, "parentTag": "grna_CashProceedsFromBusinessCombination", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash proceeds from convertible notes.", "label": "Cash Proceeds From Convertible Notes", "negatedLabel": "Less: cash proceeds from Convertible notes - PIPE Investors" } } }, "localname": "CashProceedsFromConvertibleNotes", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_CashlessWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "cashless warrant exercises.", "label": "Cashless Warrant Exercises", "terseLabel": "Legacy GreenLight cashless warrant exercises" } } }, "localname": "CashlessWarrantExercises", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsAreIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right date from which warrants or rights are issued.", "label": "Class Of Warrant Or Right Date From Which Warrants Or Rights Are Issued", "terseLabel": "Issuance Date" } } }, "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsAreIssued", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails" ], "xbrltype": "dateItemType" }, "grna_ClassOfWarrantOrRightExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right expiration period.", "label": "Class Of Warrant Or Right Expiration Period", "terseLabel": "Warrants expiration period" } } }, "localname": "ClassOfWarrantOrRightExpirationPeriod", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "durationItemType" }, "grna_ClassOfWarrantOrRightGrantDateFairValueWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Class of warrant or right grant date fair value warrant.", "label": "Class of Warrant or Right Grant Date Fair Value Warrant", "terseLabel": "Estimated fair value of warrant upon initial recognition" } } }, "localname": "ClassOfWarrantOrRightGrantDateFairValueWarrant", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_ClassOfWarrantsOrRightIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants or right issued during period.", "label": "Class Of Warrants Or Right Issued During Period", "terseLabel": "Warrants issued", "verboseLabel": "Warrants Issued" } } }, "localname": "ClassOfWarrantsOrRightIssuedDuringPeriod", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "grna_CollaborativeArrangementAggregateMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement aggregate milestone payments receivable.", "label": "Collaborative Arrangement Aggregate Milestone Payments Receivable", "terseLabel": "Collaborative arrangement aggregate milestone receivable" } } }, "localname": "CollaborativeArrangementAggregateMilestonePaymentsReceivable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables" ], "xbrltype": "stringItemType" }, "grna_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables" ], "xbrltype": "stringItemType" }, "grna_CommitmentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments (Details) [Line Items]" } } }, "localname": "CommitmentsDetailsLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "grna_CommitmentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments (Details) [Table]" } } }, "localname": "CommitmentsDetailsTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "grna_CommonStockSharesOutstandingPriorToBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares outstanding prior to business combination.", "label": "Common Stock Shares Outstanding Prior to Business Combination", "terseLabel": "Common stock, outstanding prior to the Business Combination" } } }, "localname": "CommonStockSharesOutstandingPriorToBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "sharesItemType" }, "grna_CommonStockWarrantClassifiedAsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant classified as liability.", "label": "Common Stock Warrant Classified As Liability [Member]", "terseLabel": "Common Stock Warrant Classified as Liability [Member]" } } }, "localname": "CommonStockWarrantClassifiedAsLiabilityMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "grna_CommonStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrant.", "label": "Common Stock Warrant [Member]", "terseLabel": "Common Stock Warrant" } } }, "localname": "CommonStockWarrantMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_CommonStockWarrantsClassifiedAsEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants classified as equity.", "label": "Common Stock Warrants Classified As Equity [Member]", "terseLabel": "Common Stock Warrant Classified as Equity [Member]" } } }, "localname": "CommonStockWarrantsClassifiedAsEquityMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "grna_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible note.", "label": "Convertible Note [Member]", "terseLabel": "Convertible Note [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "domainItemType" }, "grna_ConvertibleNotePipeInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible note PIPE investor.", "label": "Convertible Note PIPE Investors [Member]", "terseLabel": "Convertible Notes - PIPE Investors [Member]", "verboseLabel": "PIPE [Member]" } } }, "localname": "ConvertibleNotePipeInvestorsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "grna_ConvertibleNotesPayableGross": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail4": { "order": 0.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable gross.", "label": "Convertible Notes Payable Gross", "terseLabel": "Princpal Balance Outstanding (Convertible Note)" } } }, "localname": "ConvertibleNotesPayableGross", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "grna_ConvertibleNotesPayableUnamortizedDebtDiscount": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail4": { "order": 1.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail5": { "order": 1.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable unamortized debt discount.", "label": "Convertible Notes Payable Unamortized Debt Discount", "negatedLabel": "Unamortized Debt Discount (Convertible Note)", "terseLabel": "Unamortized Debt Discount (Convertible Note)" } } }, "localname": "ConvertibleNotesPayableUnamortizedDebtDiscount", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "grna_DebtInstrumentCurrentBorrowingsCapacityAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument current borrowings capacity amount.", "label": "Debt Instrument Current Borrowings Capacity Amount", "terseLabel": "Debt instrument Current Borrowings Capacity" } } }, "localname": "DebtInstrumentCurrentBorrowingsCapacityAmount", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_DebtInstrumentFinalPaymentFeeChargedAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument final payment fee charged as percentage of principal amount.", "label": "Debt Instrument Final Payment Fee Charged As Percentage Of Principal Amount", "terseLabel": "Debt instrument final payment fee charged as percentage of principal amount" } } }, "localname": "DebtInstrumentFinalPaymentFeeChargedAsPercentageOfPrincipalAmount", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "grna_DebtInstrumentIssuanceDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument issuance date.", "label": "Debt Instrument Issuance Date", "terseLabel": "Issuance Date(s)" } } }, "localname": "DebtInstrumentIssuanceDate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "gYearMonthItemType" }, "grna_DebtInstrumentMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, maturity month and year.", "label": "Debt Instrument, Maturity Month and Year", "terseLabel": "Maturity Date(s)" } } }, "localname": "DebtInstrumentMaturityMonthAndYear", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "gYearMonthItemType" }, "grna_DebtInstrumentsIssuanceDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Issuance Date", "label": "Debt Instruments Issuance Date", "terseLabel": "Issuance Date(s)" } } }, "localname": "DebtInstrumentsIssuanceDate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "stringItemType" }, "grna_DeferredFinancingCostsInAccruedExpensesAndAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred financing costs in accrued expenses and accounts payable.", "label": "Deferred Financing Costs In Accrued Expenses And Accounts Payable", "terseLabel": "Deferred financing costs in accrued expenses and accounts payable" } } }, "localname": "DeferredFinancingCostsInAccruedExpensesAndAccountsPayable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_DeferredFinancingCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred financing costs policy.", "label": "Deferred Financing Costs Policy [Policy Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredFinancingCostsPolicyPolicyTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grna_DeferredOfferingCost": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental cost directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "DeferredOfferingCost", "terseLabel": "Deferred offering costs", "verboseLabel": "Capitalized deferred offering costs" } } }, "localname": "DeferredOfferingCost", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs noncurrent.", "label": "Deferred Offering Costs Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "grna_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Line Items]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "grna_DescriptionofOrganizationandBusinessOperationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations (Details) [Table]" } } }, "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "grna_DevelopmentMilestoneAchievementTargetAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development milestone achievement target.", "label": "Development Milestone Achievement Target [Axis]" } } }, "localname": "DevelopmentMilestoneAchievementTargetAxis", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "grna_DevelopmentMilestoneAchievementTargetDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development milestone achievement target.", "label": "Development Milestone Achievement Target [Domain]" } } }, "localname": "DevelopmentMilestoneAchievementTargetDomain", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_ENVIPublicSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ENVI public shares", "label": "E N V I Public Shares [Member]", "terseLabel": "ENVI Public Shares [Member]" } } }, "localname": "ENVIPublicSharesMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "domainItemType" }, "grna_ENVISponsorSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ENVI sponsor shares.", "label": "E N V I Sponsor Shares [Member]", "terseLabel": "ENVI Sponsor Shares [Member]" } } }, "localname": "ENVISponsorSharesMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "domainItemType" }, "grna_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging growth company and smaller reporting company status.", "label": "Emerging Growth Company and Smaller Reporting Company Status [Policy Text Block]", "terseLabel": "Emerging Growth Company and Smaller Reporting Company Status" } } }, "localname": "EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grna_EnviTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ENVI trust.", "label": "ENVI Trust [Member]" } } }, "localname": "EnviTrustMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "domainItemType" }, "grna_EnvironmentalImpactAcquisitionCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Environmental impact acquisition corp.", "label": "Environmental Impact Acquisition Corp [Member]", "terseLabel": "Environmental Impact Acquisition Corp [Member]" } } }, "localname": "EnvironmentalImpactAcquisitionCorpMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "grna_EquipmentFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment financing.", "label": "Equipment Financing [Member]" } } }, "localname": "EquipmentFinancingMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_EventBasisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event basis.", "label": "Event Basis [Axis]" } } }, "localname": "EventBasisAxis", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_EventBasisDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Event basis.", "label": "Event Basis [Domain]" } } }, "localname": "EventBasisDomain", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsAssumedInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability warrants assumed in business combination.", "label": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability Warrants assumed in business combination", "terseLabel": "Warrants assumed in business combination" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsAssumedInBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "monetaryItemType" }, "grna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsExercisedInBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability warrants exercised in business combination.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Warrants exercised in business combination", "terseLabel": "Warrants exercised in business combination" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsExercisedInBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "monetaryItemType" }, "grna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsReclassifiedToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability warrants reclassified to equity.", "label": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability Warrants reclassified to equity", "terseLabel": "Warrants reclassified to equity" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantsReclassifiedToEquity", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "monetaryItemType" }, "grna_FairValueMeasurementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "grna_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesatfairvalueonarecurringbasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesatfairvalueonarecurringbasisLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "grna_FairValueMeasurementsDetailsScheduleofassetsandliabilitiesatfairvalueonarecurringbasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of assets and liabilities at fair value on a recurring basis [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofassetsandliabilitiesatfairvalueonarecurringbasisTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "grna_FairValueMeasurementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) [Table]" } } }, "localname": "FairValueMeasurementsDetailsTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "grna_FairValueOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrant liability", "label": "Fair Value of Warrant Liability", "terseLabel": "Fair value of warrant liability" } } }, "localname": "FairValueOfWarrantLiability", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_FirstNonExclusiveLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First non exclusive license.", "label": "First Non Exclusive License [Member]" } } }, "localname": "FirstNonExclusiveLicenseMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_GrantReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Grant receivable.", "label": "Grant Receivable", "terseLabel": "Grant receivable" } } }, "localname": "GrantReceivable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_GrantRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant Revenue [Abstract]" } } }, "localname": "GrantRevenueAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_GrantRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant Revenue [Line Items]" } } }, "localname": "GrantRevenueLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "grna_GrantRevenueTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant Revenue [Table]" } } }, "localname": "GrantRevenueTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "grna_GrantRevenueTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant revenue.", "label": "Grant Revenue [Text Block]", "terseLabel": "Grant Revenue" } } }, "localname": "GrantRevenueTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue" ], "xbrltype": "textBlockItemType" }, "grna_GreenlightBiosciencesHoldingsPbcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]", "terseLabel": "GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]" } } }, "localname": "GreenlightBiosciencesHoldingsPbcMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpenses", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenue", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "grna_GreenlightPandemicResponseIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GreenLight pandemic response, Inc.", "label": "GreenLight Pandemic Response, Inc [Member]" } } }, "localname": "GreenlightPandemicResponseIncMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_HorizonTechnologyFinanceCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Horizon technology finance corporation.", "label": "Horizon Technology Finance Corporation [Member]" } } }, "localname": "HorizonTechnologyFinanceCorporationMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_HorizonTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Horizon term loan.", "label": "Horizon Term Loan [Member]", "terseLabel": "Horizon Term Loan [Member]" } } }, "localname": "HorizonTermLoanMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued expenses and other liabilities.", "label": "Increase Decrease In Accrued Expenses And Other Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedExpensesAndOtherLiabilities", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_IncrementalStockBasedCompensationRecognizableOnEventOfBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incremental stock based compensation recognizable on event of business combination.", "label": "Incremental Stock Based Compensation Recognizable On Event Of Business Combination", "terseLabel": "Incremental stock based compensation recognizable on event of business combination" } } }, "localname": "IncrementalStockBasedCompensationRecognizableOnEventOfBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_InitialLicenseAgreementForNumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial license agreement for number of products.", "label": "Initial License Agreement for Number of Products", "terseLabel": "Initial license agreement for number of products" } } }, "localname": "InitialLicenseAgreementForNumberOfProducts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "grna_LegacyGreenlightEquityholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy greenlight equityholders.", "label": "Legacy GreenLight Equityholders [Member]", "terseLabel": "Legacy Green Light [Member]" } } }, "localname": "LegacyGreenlightEquityholdersMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_LegacyGreenlightRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy greenlight redeemable convertible preferred stock.", "label": "Legacy Greenlight Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Legacy Greenlight Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "LegacyGreenlightRedeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_LesseeOperatingLeaseMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease maturity period.", "label": "Lessee Operating Lease Maturity Period", "terseLabel": "Lessee, Operating Lease maturity period" } } }, "localname": "LesseeOperatingLeaseMaturityPeriod", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "grna_LicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Abstract]" } } }, "localname": "LicenseAgreementAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_LicenseAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement date.", "label": "License Agreement Date", "terseLabel": "License agreement date" } } }, "localname": "LicenseAgreementDate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "grna_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Text Block]", "verboseLabel": "License Agreements" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement" ], "xbrltype": "textBlockItemType" }, "grna_LicenseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreements.", "label": "License Agreements [Member]" } } }, "localname": "LicenseAgreementsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "grna_LicenseAndCollaborationAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreements.", "label": "License and Collaboration Agreements [Abstract]" } } }, "localname": "LicenseAndCollaborationAgreementsAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_LicenseAndCollaborationAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreements.", "label": "License and Collaboration Agreements [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "LicenseAndCollaborationAgreementsTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "grna_LicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License fee.", "label": "License Fee", "verboseLabel": "License Fee" } } }, "localname": "LicenseFee", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_LicensePaymentTermsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License payment terms.", "label": "License Payment Terms [Axis]" } } }, "localname": "LicensePaymentTermsAxis", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "grna_LicensePaymentTermsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License payment terms.", "label": "License Payment Terms [Domain]" } } }, "localname": "LicensePaymentTermsDomain", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_LoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]" } } }, "localname": "LoanAndSecurityAgreementMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal in year four and thereafter.", "label": "Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter", "terseLabel": "2025 and thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "grna_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeAndAfterYearThree": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term debt, maturities, repayments of principal in year three and after year three.", "label": "Long-Term Debt, Maturities, Repayments of Principal in Year Three and After Year Three", "terseLabel": "2025 and thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeAndAfterYearThree", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "grna_LongTermDebtPrepaymentAmountAsAPercentageOfPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term debt prepayment amount as a percentage of principal.", "label": "Long Term Debt Prepayment Amount As A Percentage Of Principal", "terseLabel": "Long term debt prepayment amount as a percentage of principal" } } }, "localname": "LongTermDebtPrepaymentAmountAsAPercentageOfPrincipal", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "grna_MandatoryConversionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatory conversion.", "label": "Mandatory Conversion [Member]", "terseLabel": "Mandatory Conversion [Member]" } } }, "localname": "MandatoryConversionMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_MasterEquipmentFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master equipment financing agreement.", "label": "Master Equipment Financing Agreement [Member]" } } }, "localname": "MasterEquipmentFinancingAgreementMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_MaximumManufacturingTechnologyTransferPaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum manufacturing technology transfer payments to be received.", "label": "Maximum Manufacturing Technology Transfer Payments to be Received", "terseLabel": "Maximum manufacturing technology transfer payments to be received" } } }, "localname": "MaximumManufacturingTechnologyTransferPaymentsToBeReceived", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_MaximumMilestonePaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payments to be received.", "label": "Maximum Milestone Payments to be Received", "terseLabel": "Maximum milestone payments to be received" } } }, "localname": "MaximumMilestonePaymentsToBeReceived", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_MeasurementInputFairValueOfUnderlyingCommonStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input fair value of underlying common stock warrant.", "label": "Measurement Input Fair Value of Underlying Common Stock Warrant [Member]", "terseLabel": "Fair value of common stock" } } }, "localname": "MeasurementInputFairValueOfUnderlyingCommonStockWarrantMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_MeasurementInputFairValueOfUnderlyingSeriesOfPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input fair value of underlying series of preferred stock.", "label": "Measurement Input Fair Value Of Underlying Series Of Preferred Stock [Member]", "terseLabel": "Fair value of underlying series of preferred stock [Member]" } } }, "localname": "MeasurementInputFairValueOfUnderlyingSeriesOfPreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_MilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "grna_NewGreenlightTwoThousandTwentyTwoEquityAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New GreenLight Two Thousand Twenty Two equity and incentive plan.", "label": "New GreenLight Two Thousand Twenty Two Equity and Incentive Plan [Member]", "terseLabel": "New GreenLight 2022 Equity and Incentive Plan [Member]" } } }, "localname": "NewGreenlightTwoThousandTwentyTwoEquityAndIncentivePlanMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_NonCashEquipmentFinancingIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash equipment financing issuance costs.", "label": "Non Cash Equipment Financing Issuance Costs", "terseLabel": "Non-cash equipment financing issuance costs" } } }, "localname": "NonCashEquipmentFinancingIssuanceCosts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_NoncashOrPartNoncashAcquisitionLiabilitiesAssumedWarrants": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 4.0, "parentTag": "grna_ReverseMergerNetOfTransactionsCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash acquisition liabilities assumed warrants.", "label": "Noncash Or Part Noncash Acquisition Liabilities Assumed Warrants", "negatedLabel": "Less: warrant liabilities assumed", "terseLabel": "Warrant liabilities assumed in the Business Combination" } } }, "localname": "NoncashOrPartNoncashAcquisitionLiabilitiesAssumedWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_NoncashOrPartNoncashAcquisitionTransactionCostsPaid": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 2.0, "parentTag": "grna_ReverseMergerNetOfTransactionsCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash acquisition transaction costs paid.", "label": "Noncash Or Part Noncash Acquisition Transaction Costs Paid", "negatedLabel": "Less: transaction costs paid in 2021" } } }, "localname": "NoncashOrPartNoncashAcquisitionTransactionCostsPaid", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_NoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncurrent assets.", "label": "Noncurrent Assets [Member]", "terseLabel": "Noncurrent Assets [Member]" } } }, "localname": "NoncurrentAssetsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "grna_NumberOfSharesOfCommonStockIssuableUponConversionOfEachShareOfTemporaryEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issuable upon conversion of each share of temporary equity.", "label": "Number Of Shares Of Common Stock Issuable Upon Conversion Of Each Share Of Temporary Equity", "terseLabel": "Number of shares of common stock issuable upon conversion of each share of temporary equity" } } }, "localname": "NumberOfSharesOfCommonStockIssuableUponConversionOfEachShareOfTemporaryEquity", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "grna_NumberOfWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Number of Warrants Issued", "terseLabel": "Warrants issued", "verboseLabel": "Issued" } } }, "localname": "NumberOfWarrantsIssued", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "sharesItemType" }, "grna_OperatingLeaseCommencementDateOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement date of Contract", "label": "Operating Lease Commencement Date Of Contract", "terseLabel": "Lease, Operating Lease Commencement Date" } } }, "localname": "OperatingLeaseCommencementDateOfContract", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "gYearMonthItemType" }, "grna_OperatingLeaseExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expiration date", "label": "Operating Lease Expiration Date", "terseLabel": "Lease, Operating Lease Expiration Date" } } }, "localname": "OperatingLeaseExpirationDate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "gYearMonthItemType" }, "grna_OperatingLeaseLiabilitiesGrossDifferenceAmountLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities gross difference amount.", "label": "Operating Lease Liabilities Gross Difference Amount [Line Items]" } } }, "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "grna_OperatingLeaseLiabilitiesGrossDifferenceAmountTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities gross difference amount.", "label": "Operating Lease Liabilities Gross Difference Amount [Table]" } } }, "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "grna_OperatingLeasesFutureMinimumPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating leases future minimum payments due after year four.", "label": "Operating Leases Future Minimum Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAfterYearFour", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "grna_OptionExerciseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Option exercise fee.", "label": "Option Exercise Fee", "verboseLabel": "Option exercise fee" } } }, "localname": "OptionExerciseFee", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_OptionToIncreaseLicenseAgreementForNumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to increase license agreement for number of products.", "label": "Option to Increase License Agreement for Number of Products", "terseLabel": "Option to increase license agreement for number of products" } } }, "localname": "OptionToIncreaseLicenseAgreementForNumberOfProducts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "grna_OptionToPurchaseDevelopedResearchPlanAndClinicalTrialDataForPercentageOfActualCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to purchase developed research plan and clinical trial data for percentage of actual cost.", "label": "Option to Purchase Developed Research Plan and Clinical Trial Data for Percentage of Actual Cost", "terseLabel": "Option to purchase developed research plan and clinical trial data for percentage of actual cost" } } }, "localname": "OptionToPurchaseDevelopedResearchPlanAndClinicalTrialDataForPercentageOfActualCost", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "grna_OtherFundingCommitmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Funding Commitments [Member].", "label": "Other Funding Commitments [Member]" } } }, "localname": "OtherFundingCommitmentsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "grna_PercentageIncreaseDecreaseInBaseLeaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase decrease in base lease rent.", "label": "Percentage Increase Decrease In Base Lease Rent", "terseLabel": "Percentage increase decrease in base lease rent" } } }, "localname": "PercentageIncreaseDecreaseInBaseLeaseRent", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "grna_PerformanceBasedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Based Options [Member].", "label": "Performance Based Options [Member]" } } }, "localname": "PerformanceBasedOptionsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_PipeInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PIPE Investors.", "label": "PIPE Investors [Member]", "terseLabel": "PIPE Investors [Member]" } } }, "localname": "PipeInvestorsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "domainItemType" }, "grna_PowerscourtInvestmentsXxvLpHorizonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Powerscourt investments xxv, lp (horizon).", "label": "Powerscourt Investments XXV, LP (Horizon) [Member]" } } }, "localname": "PowerscourtInvestmentsXxvLpHorizonMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_PreferredStockWarrantsClassifiedAsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock warrants classified as liabilities.", "label": "Preferred Stock Warrants Classified As Liabilities [Member]" } } }, "localname": "PreferredStockWarrantsClassifiedAsLiabilitiesMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_PreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Warrants [Member]", "terseLabel": "Preferred Stock Warrants" } } }, "localname": "PreferredStockWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_PrepaymentYearOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment year one.", "label": "Prepayment Year One [Member]" } } }, "localname": "PrepaymentYearOneMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_PrepaymentYearThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment year three.", "label": "Prepayment Year Three [Member]" } } }, "localname": "PrepaymentYearThreeMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_PrepaymentYearTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment year two.", "label": "Prepayment Year Two [Member]" } } }, "localname": "PrepaymentYearTwoMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_PrincipalPaymentsOnCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal payments on capital lease obligations.", "label": "Principal Payments on Capital Lease Obligations", "negatedLabel": "Principal payments on capital lease obligations" } } }, "localname": "PrincipalPaymentsOnCapitalLeaseObligations", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrants", "label": "Private Placement Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_ProceedsFromBusinessCombinationNetOfTransactionCosts": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from business combination net of transaction costs.", "label": "Proceeds from Business Combination Net of Transaction costs", "terseLabel": "Proceeds from business combination, net of of transaction costs" } } }, "localname": "ProceedsFromBusinessCombinationNetOfTransactionCosts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_ProceedsFromEquipmentFinancing1": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from equipment financing.", "label": "Proceeds From Equipment Financing1", "terseLabel": "Proceeds from equipment financing" } } }, "localname": "ProceedsFromEquipmentFinancing1", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_PublicAndPrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public and private placement warrants.", "label": "Public and Private Placement Warrants [Member]" } } }, "localname": "PublicAndPrivatePlacementWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "grna_PublicWarrantsExercisedPostBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public warrants exercised post business combination.", "label": "Public Warrants Exercised Post Business Combination", "negatedLabel": "Exercised subsequent to the business combination", "terseLabel": "Exercised subsequent to the business combination" } } }, "localname": "PublicWarrantsExercisedPostBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "sharesItemType" }, "grna_PublicWarrantsExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public warrants exercises", "label": "Public Warrants Exercises", "negatedLabel": "Public warrants exercises", "terseLabel": "Public warrants exercises" } } }, "localname": "PublicWarrantsExercises", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "grna_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public warrants.", "label": "PublicWarrantsMember", "terseLabel": "Public Warrants [Member]", "verboseLabel": "Public [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "grna_RedemptionOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of common shares.", "label": "Redemption of Common Shares", "negatedLabel": "Less: Redemption of ENVI shares" } } }, "localname": "RedemptionOfCommonShares", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "sharesItemType" }, "grna_RedemptionOfPublicWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of redemption of public warrants.", "label": "RedemptionOfPublicWarrants", "terseLabel": "Description of redemption of public warrants" } } }, "localname": "RedemptionOfPublicWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_RepaymentsOfTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of tenant improvement allowance.", "label": "Repayments of Tenant Improvement Allowance", "negatedLabel": "Repayments of tenant improvement allowance" } } }, "localname": "RepaymentsOfTenantImprovementAllowance", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_ResearchAndDevelopmentsCostsAssociatedWithGrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and developments costs associated with grant.", "label": "Research and Developments Costs Associated With Grant", "terseLabel": "Research and developments costs associated with grant" } } }, "localname": "ResearchAndDevelopmentsCostsAssociatedWithGrant", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "REVENUE:" } } }, "localname": "RevenueAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "grna_ReverseMergerNetOfTransactionsCosts": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reverse merger, net of transactions costs.", "label": "Reverse Merger, Net of Transactions Costs", "totalLabel": "Reverse merger, net of transactions costs" } } }, "localname": "ReverseMergerNetOfTransactionsCosts", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "grna_ScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assets and liabilities at fair value on a recurring basis [Abstract]" } } }, "localname": "ScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasisAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_ScheduleOfConsolidatedStatementOfOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Consolidated Statement of Operations [Table Text Block]", "label": "Schedule of Restatement Consolidated Statement of Operations" } } }, "localname": "ScheduleOfConsolidatedStatementOfOperationsTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "grna_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of estimated useful lives of property and equipment.", "label": "Schedule of Estimated Useful Lives of Property And Equipment [Table Text Block]", "terseLabel": "Summary of Estimated Useful Lives of Property and Equipment" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "grna_ScheduleOfInterestExpenseDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expense debt.", "label": "Schedule Of Interest Expense Debt [Line Items]" } } }, "localname": "ScheduleOfInterestExpenseDebtLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail" ], "xbrltype": "stringItemType" }, "grna_ScheduleOfInterestExpenseDebtTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expense debt.", "label": "Schedule Of Interest Expense Debt [Table]" } } }, "localname": "ScheduleOfInterestExpenseDebtTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail" ], "xbrltype": "stringItemType" }, "grna_ScheduleOfInterestExpenseDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of interest expense debt.", "label": "Schedule Of Interest Expense Debt [Table Text Block]", "terseLabel": "Summary of Interest Expense" } } }, "localname": "ScheduleOfInterestExpenseDebtTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "grna_ScheduleOfMaturitiesOfLongTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of maturities of long term debt.", "label": "Schedule Of Maturities Of Long Term Debt [Line Items]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "stringItemType" }, "grna_ScheduleOfMaturitiesOfLongTermDebtTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of maturities of long term debt.", "label": "Schedule Of Maturities Of Long Term Debt [Table]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "stringItemType" }, "grna_ScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of number of shares of common stock outstanding immediately consummation of business combination.", "label": "Schedule of Number of Shares of Common Stock Outstanding Immediately Consummation of Business Combination [Table Text Block]", "terseLabel": "Schedule of Number of Shares of Common Stock Outstanding and Immediately Consummation of Business Combination" } } }, "localname": "ScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "grna_ScheduleOfRestatementEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Restatement Earnings Per Share Basic And Diluted.", "label": "Schedule of Restatement Earnings Per Share Basic and Diluted" } } }, "localname": "ScheduleOfRestatementEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "grna_SecondNonExclusiveLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second non exclusive license.", "label": "Second Non Exclusive License [Member]" } } }, "localname": "SecondNonExclusiveLicenseMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_SeriesA1RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A1 redeemable convertible preferred stock.", "label": "Series A1 Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A1 Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesA1RedeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesA2PreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A2 preferred stock warrants.", "label": "Series A2 Preferred Stock Warrants [Member]" } } }, "localname": "SeriesA2PreferredStockWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesA2redeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A2redeemable convertible preferred stock.", "label": "Series A2redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A 2Redeemable Convertible Preferred Stock [Member]", "verboseLabel": "Series A2 Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesA2redeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesA3PreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A3 preferred stock warrants.", "label": "Series A3 Preferred Stock Warrants [Member]" } } }, "localname": "SeriesA3PreferredStockWarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesA3redeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A3redeemable convertible preferred stock.", "label": "Series A3redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A 3Redeemable Convertible Preferred Stock [Member]", "verboseLabel": "Series A3 Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesA3redeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesBRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B redeemable convertible preferred stock.", "label": "Series B Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesCRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C redeemable convertible preferred stock.", "label": "Series C Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCRedeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SeriesDRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D redeemable convertible preferred stock.", "label": "Series D Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series D Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDRedeemableConvertiblePreferredStockMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_SerumInstituteOfIndiaPrivateLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Serum Institute of India Private Limited [Member]", "terseLabel": "SIIPL [Member]" } } }, "localname": "SerumInstituteOfIndiaPrivateLimitedMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "grna_ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedVestingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share based payment award modified vesting date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Modified Vesting Date", "terseLabel": "Share-based compensation arrangement by share based payment award modified vesting date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardModifiedVestingDate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "grna_ShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValueOnHighLevelOfPerformance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based payment award fair value assumptions grant date fair value on high level of performance.", "label": "Share Based Payment Award Fair Value Assumptions Grant Date Fair Value On High Level Of Performance", "terseLabel": "Share based payment award fair value assumptions grant date fair value on high level of performance" } } }, "localname": "ShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValueOnHighLevelOfPerformance", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_ShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValueOnNonProbableOutcome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based payment award fair value assumptions grant date fair value on non probable outcome.", "label": "Share Based Payment Award Fair Value Assumptions Grant Date Fair Value On Non Probable Outcome", "terseLabel": "Share based payment award fair value assumptions grant date fair value on non probable outcome" } } }, "localname": "ShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValueOnNonProbableOutcome", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_ShareBasedPaymentAwardFairValueAssumptionsGrantDateModificationFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based payment award fair value assumptions grant date modification fair value.", "label": "Share Based Payment Award Fair Value Assumptions Grant Date Modification Fair Value", "terseLabel": "Share based payment award fair value assumptions grant date modification fair value" } } }, "localname": "ShareBasedPaymentAwardFairValueAssumptionsGrantDateModificationFairValue", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_SharesIssuedInBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in business combination.", "label": "Shares Issued in Business Combination", "terseLabel": "Shares issued" } } }, "localname": "SharesIssuedInBusinessCombination", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "sharesItemType" }, "grna_SharesIssuedInBusinessCombinationAndPrivateInvestmentInPublicEquityFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in business combination and private investment in public equity financing.", "label": "Shares Issued in Business Combination and Private Investment in Public Equity Financing", "terseLabel": "Business combination and PIPE financing shares" } } }, "localname": "SharesIssuedInBusinessCombinationAndPrivateInvestmentInPublicEquityFinancing", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "sharesItemType" }, "grna_SharesIssuedInPrivateInvestmentInPublicEquityFinancing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in private investment in public equity financing.", "label": "Shares Issued in Private Investment in Public Equity Financing", "terseLabel": "Shares issued in PIPE financing" } } }, "localname": "SharesIssuedInPrivateInvestmentInPublicEquityFinancing", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails" ], "xbrltype": "sharesItemType" }, "grna_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon valley bank.", "label": "Silicon Valley Bank [Member]" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_SiliconValleyBankTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon valley bank term loan [Member].", "label": "Silicon Valley Bank Term Loan [Member]", "terseLabel": "Silicon Valley Bank Term Loan [Member]" } } }, "localname": "SiliconValleyBankTermLoanMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "domainItemType" }, "grna_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, exercise of common stock warrants.", "label": "Stock Issued During Period, Shares, Exercise of Common Stock Warrants", "terseLabel": "Cashless exercise of Legacy GreenLight common stock warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "grna_StockIssuedDuringPeriodSharesExerciseOfPublicWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, exercise of public warrants.", "label": "Stock Issued During Period, Shares, Exercise of Public Warrants", "terseLabel": "Exercise of public warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfPublicWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "grna_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, exercise of common stock warrants.", "label": "Stock Issued During Period, Value, Exercise of Common Stock Warrants", "terseLabel": "Cashless exercise of Legacy GreenLight common stock warrants" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_StockIssuedDuringPeriodValueExerciseOfPublicWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, exercise of public warrants.", "label": "Stock Issued During Period, Value, Exercise of Public Warrants", "terseLabel": "Exercise of public warrants" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfPublicWarrants", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_StockWarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock warrants.", "label": "Stock Warrants [Policy Text Block]", "terseLabel": "Warrants" } } }, "localname": "StockWarrantsPolicyTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "grna_StockholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Line Items]" } } }, "localname": "StockholdersEquityDetailsLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_StockholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Table]" } } }, "localname": "StockholdersEquityDetailsTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_SummaryOfEstimatedTheFairValueOfTheWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of estimated the fair value of the warrants.", "label": "Summary of Estimated the Fair Value of The Warrants [Abstract]" } } }, "localname": "SummaryOfEstimatedTheFairValueOfTheWarrantsAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_SummaryOfPreferredStockWarrantsClassifiedAsLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of preferred stock warrants classified as liabilities.", "label": "Summary of Preferred Stock Warrants Classified As Liabilities [Abstract]" } } }, "localname": "SummaryOfPreferredStockWarrantsClassifiedAsLiabilitiesAbstract", "nsuri": "http://greenlightbiosciences.com/20220331", "xbrltype": "stringItemType" }, "grna_SummaryOfRollForwardOfWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of roll forward of warrants.", "label": "Summary of Roll Forward of Warrants [Table Text Block]", "terseLabel": "Summary of Roll-forward of the Warrants" } } }, "localname": "SummaryOfRollForwardOfWarrantsTableTextBlock", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "grna_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "grna_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "grna_TargetOneAndTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Target one and two.", "label": "Target One And Two [Member]" } } }, "localname": "TargetOneAndTwoMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_TargetThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Target three.", "label": "Target Three [Member]" } } }, "localname": "TargetThreeMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_TechnologyAccessFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Technology access fee.", "label": "Technology Access Fee", "verboseLabel": "Technology Access Fee" } } }, "localname": "TechnologyAccessFee", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "grna_TemporaryEquityConversionBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity conversion basis.", "label": "Temporary Equity Conversion Basis", "terseLabel": "Temporary equity conversion basis" } } }, "localname": "TemporaryEquityConversionBasis", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_TemporaryEquityConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity conversion price.", "label": "Temporary Equity Conversion Price", "terseLabel": "Temporary equity conversion price" } } }, "localname": "TemporaryEquityConversionPrice", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "grna_TemporaryEquityCumulativeDividendAccrualRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, cumulative dividend accrual rate.", "label": "Temporary Equity Cumulative Dividend Accrual Rate", "terseLabel": "Temporary equity, Cumulative dividend accrual rate" } } }, "localname": "TemporaryEquityCumulativeDividendAccrualRate", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "grna_TemporaryEquityStockIssuedDuringPeriodSharesExerciseOfCovertiblePreferredStockWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares exercise of covertible preferred stock warrant.", "label": "Temporary Equity Stock Issued During Period Shares Exercise of Covertible Preferred Stock Warrant", "terseLabel": "Cashless exercise of Legacy GreenLight preferred stock warrants (in Shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesExerciseOfCovertiblePreferredStockWarrant", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "grna_TemporaryEquityVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, Voting rights", "label": "Temporary Equity Voting Rights", "terseLabel": "Temporary equity, Voting rights" } } }, "localname": "TemporaryEquityVotingRights", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_ThirdNonExclusiveLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third non exclusive license.", "label": "Third Non Exclusive License [Member]" } } }, "localname": "ThirdNonExclusiveLicenseMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_TotalDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Debt", "label": "Total Debt [Member]", "terseLabel": "Total Debt" } } }, "localname": "TotalDebtMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "grna_TrinityCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trinity capital.", "label": "Trinity Capital [Member]" } } }, "localname": "TrinityCapitalMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_TrinityEquipmentFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trinity equipment financing.", "label": "Trinity Equipment Financing [Member]", "terseLabel": "Trinity equipment financing [Member]" } } }, "localname": "TrinityEquipmentFinancingMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "domainItemType" }, "grna_TwoThousandAndTwentyNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty notes.", "label": "Two Thousand And Twenty Notes [Member]", "terseLabel": "Two Thousand And Twenty Notes [Member]" } } }, "localname": "TwoThousandAndTwentyNotesMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "domainItemType" }, "grna_TwoThousandAndTwentyOnePipeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one pipe notes.", "label": "Two Thousand And Twenty One PIPE Notes [Member]" } } }, "localname": "TwoThousandAndTwentyOnePipeNotesMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "grna_UpfrontLicenseFeeToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront license fee to be received.", "label": "Upfront License Fee to be Received", "terseLabel": "Upfront license fee to be received" } } }, "localname": "UpfrontLicenseFeeToBeReceived", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "grna_WarrantLiabilities": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liabilities.", "label": "WarrantLiabilities", "terseLabel": "Warrant liabilities" } } }, "localname": "WarrantLiabilities", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "grna_WarrantStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant strike price.", "label": "Warrant Strike Price", "terseLabel": "Strike price" } } }, "localname": "WarrantStrikePrice", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "perShareItemType" }, "grna_WarrantsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Line Items]", "terseLabel": "Class of Warrant or Right Exercised During Period" } } }, "localname": "WarrantsDetailsLineItems", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_WarrantsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants (Details) [Table]" } } }, "localname": "WarrantsDetailsTable", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "grna_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants.", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://greenlightbiosciences.com/20220331", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage" ], "xbrltype": "domainItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Financial Statements, Captions [Line Items]" } } }, "localname": "CondensedFinancialStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r59", "r61", "r107", "r108", "r241", "r284" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r240", "r283", "r326", "r329", "r465", "r466", "r467", "r468", "r469", "r470", "r489", "r534", "r535", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r240", "r283", "r326", "r329", "r465", "r466", "r467", "r468", "r469", "r470", "r489", "r534", "r535", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r240", "r283", "r315", "r326", "r329", "r465", "r466", "r467", "r468", "r469", "r470", "r489", "r534", "r535", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r240", "r283", "r315", "r326", "r329", "r465", "r466", "r467", "r468", "r469", "r470", "r489", "r534", "r535", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r60", "r61", "r107", "r108", "r241", "r284" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r121", "r122", "r124", "r125", "r140", "r409", "r410" ], "lang": { "en-us": { "role": { "label": "Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r140", "r191", "r192", "r365", "r380", "r408", "r409", "r410", "r411", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r140", "r191", "r192", "r365", "r380", "r408", "r409", "r410", "r411", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "auth_ref": [ "r1", "r114", "r115", "r119", "r126", "r191", "r192", "r365", "r380", "r408", "r411", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]", "terseLabel": "Retroactive Application of Business Combination" } } }, "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r120", "r327" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r111", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r124", "r125", "r140", "r191", "r192", "r365", "r380", "r408", "r409", "r410", "r411", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r574", "r575" ], "lang": { "en-us": { "role": { "label": "As Reported [Member]", "terseLabel": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r120", "r126", "r327" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r109", "r394" ], "lang": { "en-us": { "role": { "label": "Condensed Financial Statements [Table]" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r120", "r126", "r221", "r327", "r457" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r27", "r181", "r182" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r12", "r13", "r43" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r37", "r211" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r365", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r111", "r112", "r113", "r362", "r363", "r364", "r409" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r330", "r332", "r368", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r332", "r358", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r73", "r89", "r260", "r435" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r71", "r89", "r260", "r437" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred finance costs", "verboseLabel": "Non-cash amortization of debt discount and deferred financing cost" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r104", "r161", "r170", "r176", "r189", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r396", "r400", "r425", "r452", "r454", "r507", "r523" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r56", "r104", "r189", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r396", "r400", "r425", "r452", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r413" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r333", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r325", "r328" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r325", "r328", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "negatedLabel": "Less: accrued transaction costs at March 31, 2022", "terseLabel": "Less: accrued transaction costs at March 31, 2022", "verboseLabel": "Business combination transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Purchase price" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business combination transaction cost" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATION" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment included in accrued expenses and accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligations": { "auth_ref": [ "r22", "r446", "r525" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.", "label": "Capital Lease Obligations", "terseLabel": "Capital Lease, Debt Balance", "totalLabel": "Capital lease, Debt Balance" } } }, "localname": "CapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total gross amount less the charge for the use of the long-lived depreciable assets subject to a lease meeting the criteria for capitalization.", "label": "Capital Leases, Balance Sheet, Assets by Major Class, Net", "terseLabel": "Capital lease assets", "totalLabel": "Capital Leases, Balance Sheet, Assets by Major Class, Net, Total" } } }, "localname": "CapitalLeasesBalanceSheetAssetsByMajorClassNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation": { "auth_ref": [ "r440", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.", "label": "Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation", "terseLabel": "Capital lease accumulated amortization" } } }, "localname": "CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.", "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r34", "r91" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash \u2013 Ending", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "terseLabel": "Cash and cash equivalents:", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r16", "r92", "r505" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r91", "r97" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r426" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r101", "r104", "r129", "r130", "r131", "r134", "r136", "r144", "r145", "r146", "r189", "r225", "r229", "r230", "r231", "r234", "r235", "r281", "r282", "r286", "r290", "r425", "r565" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r303", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class Of Warrant Or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Fair value of common stock", "terseLabel": "Warrants price per share (in Dollars per share)", "verboseLabel": "Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of warrant or right, number of securities called by warrants or rights", "terseLabel": "Shares issued", "verboseLabel": "Shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants Outstanding, Ending balance", "periodStartLabel": "Warrants Outstanding, Beginning balance", "terseLabel": "Warrants outstanding", "verboseLabel": "Number of warrants or rights outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r303", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfRollforwardOfTheWarrantsParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement [Member]" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r220", "r512", "r529" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r217", "r218", "r219", "r222", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock", "verboseLabel": "Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, capital shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r111", "r112", "r409" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Total shares of common stock immediately after business combination" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 500,000,000 and 191,500,000 shares authorized, 122,980,505 and 96,575,107 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r149", "r521" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r22", "r509", "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible notes", "totalLabel": "Convertible Debt, Total", "verboseLabel": "Carrying value of convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Fair value of convertible debt" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r236", "r237", "r238", "r240", "r250", "r251", "r252", "r256", "r257", "r258", "r259", "r260", "r268", "r269", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible debt with accrued interest", "verboseLabel": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r49" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail5": { "order": 0.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Debt payable", "verboseLabel": "Total debt and convertible notes" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r22", "r509", "r524", "r546" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail4": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail5": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "terseLabel": "Debt Balance (Convertible Note)", "totalLabel": "Debt Balance (Convertible Note)" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r94", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Conversion of convertible debt to equity" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Debt conversion, converted instrument, shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r100", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r254", "r261", "r262", "r264", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r21", "r22", "r103", "r109", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r268", "r269", "r270", "r271", "r438", "r508", "r509", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r265", "r509", "r522" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Debt instrument, Carrying amount", "verboseLabel": "Principal Balance Outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r45", "r238" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument interest rate", "verboseLabel": "Stated Interest Rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Maturity Date(s)" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, End", "terseLabel": "Debt instrument maturity date", "verboseLabel": "Debt Instrument Maturity Date" } } }, "localname": "DebtInstrumentMaturityDateRangeEnd1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, Start", "terseLabel": "Debt instrument maturity date", "verboseLabel": "Debt Instrument Maturity Date" } } }, "localname": "DebtInstrumentMaturityDateRangeStart1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r49", "r103", "r109", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r268", "r269", "r270", "r271", "r438" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r47", "r518" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Long-term debt repayment period in months" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r103", "r109", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r263", "r268", "r269", "r270", "r271", "r298", "r299", "r300", "r301", "r435", "r436", "r438", "r439", "r520" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r250", "r435", "r439" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized Debt Discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt instrument, Remaining borrowing capacity", "verboseLabel": "Debt Instrument Unused Borrowing Capacity" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance cost", "verboseLabel": "Debt Issuance Cost" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current portion", "totalLabel": "Deferred Revenue, Current, Total", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "totalLabel": "Deferred Revenue, Noncurrent, Total" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r89", "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r159" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Fair value of warrants in debt issuance cost", "totalLabel": "Derivative, Fair Value, Net, Total", "verboseLabel": "Fair Value Of warrants In Debt Issuance Cost" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r407", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "WARRANTS" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/Warrants" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r57", "r58", "r61", "r424" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Warrant liabilities", "totalLabel": "Derivative Liability, Total", "verboseLabel": "Fair Value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopmentCosts": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.", "label": "Development Costs, Period Cost", "verboseLabel": "Development Costs, Period Cost" } } }, "localname": "DevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r302", "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends", "totalLabel": "Dividends, Total" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total", "verboseLabel": "Net loss per share available to common stockholders-basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r137", "r138", "r139", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share based payment arrangement nonvested award cost not yet recognized period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to Purchase Common Stock", "verboseLabel": "Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r64", "r65", "r66", "r111", "r112", "r113", "r115", "r122", "r125", "r143", "r190", "r297", "r302", "r362", "r363", "r364", "r379", "r380", "r409", "r427", "r428", "r429", "r430", "r431", "r432", "r536", "r537", "r538", "r575" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r89", "r275" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of warrant liability", "verboseLabel": "Fair value of the warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Estimated Fair Value of the Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r252", "r268", "r269", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r414", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r413", "r414", "r416", "r417", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r252", "r316", "r317", "r322", "r324", "r414", "r462" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r252", "r268", "r269", "r316", "r317", "r322", "r324", "r414", "r463" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r252", "r268", "r269", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r414", "r464" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r418", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r419" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value ending", "periodStartLabel": "Fair value beginning" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfLevel3WarrantLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r252", "r268", "r269", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r420", "r423" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r263", "r295", "r407", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Gain on disposal of property and equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r89", "r272", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r204", "r205", "r454", "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r89", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of long lived asset" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r206", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r38", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Acquired In-process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r213", "r216" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r105", "r375", "r377", "r378", "r381", "r383", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r124", "r125", "r160", "r374", "r382", "r384", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense benefit", "totalLabel": "Income tax provision", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r158", "r434", "r437", "r514" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Total", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r73", "r258", "r267", "r270", "r271" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r75", "r259", "r270", "r271" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail": { "order": 0.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "verboseLabel": "Interest paid or accrued" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfInterestExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r82", "r86", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r511", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "totalLabel": "Operating Leases, Rent Expense, Total", "verboseLabel": "Base lease rent" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements [Member]", "verboseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r42", "r104", "r171", "r189", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r397", "r400", "r401", "r425", "r452", "r453" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r104", "r189", "r425", "r454", "r510", "r527" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r44", "r104", "r189", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r397", "r400", "r401", "r425", "r452", "r453", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r413" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r22", "r509", "r522" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long Term Debt", "totalLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r41", "r103" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Debt instrument, Current borrowings capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Interest Rate" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r41", "r103" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Debt Instrument Advances Drawn" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Debt Instrument Remaining Borrowings Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r251", "r266", "r268", "r269", "r509", "r525" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Debt Balance", "verboseLabel": "Debt Balance" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r22" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "totalLabel": "Long-term Debt and Lease Obligation, Total", "verboseLabel": "Total Long-Term" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail2": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "negatedTerseLabel": "Less: Current Portion", "totalLabel": "Long-term Debt and Lease Obligation, Current, Total" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r109", "r223", "r256" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r109", "r223", "r256" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r109", "r223", "r256" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r109" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022", "verboseLabel": "Remainder of 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtSummaryOfFuturePrincipalPaymentOfLongTermDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r49", "r224" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureDebtSummaryOfOutstandingDebtDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management Fee Expense", "verboseLabel": "Management Fee Expense" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Strike Price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Estimated time [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected / Implied volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r87", "r90" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r62", "r63", "r66", "r69", "r90", "r104", "r114", "r116", "r117", "r119", "r120", "r124", "r125", "r132", "r161", "r169", "r172", "r175", "r177", "r189", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r411", "r425", "r513", "r531" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Loss", "totalLabel": "Net loss attributable to common stockholders", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r116", "r117", "r119", "r120", "r127", "r128", "r133", "r136", "r161", "r169", "r172", "r175", "r177" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss available to common stockholders", "verboseLabel": "Net loss available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "auth_ref": [ "r94", "r95", "r96" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails": { "order": 6.0, "parentTag": "grna_ReverseMergerNetOfTransactionsCosts", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "negatedLabel": "Less: net liabilities assumed in the Business Combination", "terseLabel": "Less: net liabilities assumed in the Business Combination", "totalLabel": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r169", "r172", "r175", "r177" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r441", "r442" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r441", "r442" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r441", "r442" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2026" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r441", "r442" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r441", "r442" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r14", "r43" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other Commitment", "totalLabel": "Other Commitment, Total" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Intangible assets" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r43", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r20", "r21" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Current", "terseLabel": "Long-term debt, current portion" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Noncurrent", "terseLabel": "Long-term debt, net of current portion" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r74" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedTotalLabel": "Total other (expense), net", "totalLabel": "Total other (expense), net" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonrecurringIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonrecurring (Income) Expense [Abstract]", "verboseLabel": "OTHER (EXPENSE) INCOME" } } }, "localname": "OtherNonrecurringIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r333", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r281" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r281" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred Stock Shares outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred Stock, $0.001 par value; 10,000,000 shares authorized, no shares issues and outstanding at March 31, 2022 and December 31, 2021, respectively", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r202", "r203" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r80" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible debt - PIPE Investors", "terseLabel": "Proceeds from issuance of Convertible Debt", "verboseLabel": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Proceeds from divestiture of businesses", "totalLabel": "Proceeds from Divestiture of Businesses, Net of Cash Divested, Total" } } }, "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from debt financing", "verboseLabel": "Proceeds from term loan facility" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of Series D Preferred Stock", "verboseLabel": "Proceeds from issuance of Series preferred stock" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "terseLabel": "Proceeds from Legal Settlements" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r79", "r361" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r79" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Exercise of public warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r62", "r63", "r66", "r83", "r104", "r114", "r124", "r125", "r161", "r169", "r172", "r175", "r177", "r189", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r395", "r398", "r399", "r402", "r403", "r411", "r425", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r37", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r215", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "verboseLabel": "Property, Plant and Equipment, Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r36", "r210" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r212", "r454", "r516", "r528" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r35", "r212", "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r210" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "durationItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]" } } }, "localname": "RedeemableNoncontrollingInterestByLegalEntityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": { "auth_ref": [ "r277", "r278", "r279", "r280" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.", "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount", "terseLabel": "LEGACY REDEEMABLE CONVERTIBLE PREFERRED STOCK (Note 12)", "verboseLabel": "Redeemable convertible preferred stock" } } }, "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Redeemable Noncontrolling Interest [Line Items]" } } }, "localname": "RedeemableNoncontrollingInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemablePreferredStockDividends": { "auth_ref": [ "r128", "r297", "r302" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.", "label": "Redeemable Preferred Stock Dividends", "negatedLabel": "Less: Accruals of dividends of preferred stock" } } }, "localname": "RedeemablePreferredStockDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r323", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r323", "r448", "r451", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r81" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Principal payments on debt", "terseLabel": "Convertible instruments, surrendered and cancelled" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r372", "r490", "r558" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r372" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementConsolidatedStatementOfOperationsDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetailsScheduleOfAssetsAndLiabilitiesAtFairValueOnARecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r10", "r19", "r91", "r97", "r547" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r302", "r365", "r454", "r526", "r540", "r545" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r111", "r112", "r113", "r115", "r122", "r125", "r190", "r362", "r363", "r364", "r379", "r380", "r409", "r536", "r538" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r99", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Contract Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r68" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Grant revenue" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/GrantRevenueAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionDeferredRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.", "label": "Revenue Recognition, Deferred Revenue [Policy Text Block]", "terseLabel": "Deferred Revenue" } } }, "localname": "RevenueRecognitionDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionForAlternativeRevenueProgramsPolicy": { "auth_ref": [ "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition related to alternative revenue programs. The major alternative revenue programs can generally be segregated into two categories, programs that adjust billings for the effects of weather abnormalities or broad external factors or to compensate the utility for demand-side management initiatives (for example, no-growth plans and similar conservation efforts); and programs that provide for additional billings (incentive awards) if the utility achieves certain objectives, such as reducing costs, reaching specified milestones, or demonstratively improving customer service.", "label": "Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block]", "terseLabel": "Grant Revenue" } } }, "localname": "RevenueRecognitionForAlternativeRevenueProgramsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r68", "r104", "r156", "r157", "r168", "r173", "r174", "r178", "r179", "r180", "r189", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r425", "r515" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of the excluded potential common stock" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationScheduleOfNumberOfSharesOfCommonStockOutstandingImmediatelyConsummationOfBusinessCombinationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationSummaryOfReconcilesElementsOfBusinessCombinationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of Reconciles Elements of Business Combination" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of changes in the fair value of Level 3 warrant liabilities" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Summary of the Outstanding Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income (loss) per common share", "verboseLabel": "Summary of the computation of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r129", "r130", "r134", "r136", "r141" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r332", "r357", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r332", "r357", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Summary of future minimum lease payments under noncancelable operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Scheduled Future Principal Payments on Total Outstanding Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r37", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNet", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/PropertyAndEquipmentNetTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r333", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r338", "r346", "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Fair Value Assumptions of Stock Option Awards Estimated on Grant Date" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r303", "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Common Stock Warrant Classified" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r167", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "verboseLabel": "Operating Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, Unvested shares", "periodStartLabel": "Beginning balance, Unvested shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted- Average Grant-Date Fair Value", "periodStartLabel": "Beginning balance, Weighted- Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of restricted stock vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted- Average Grant-Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price", "verboseLabel": "Fair value of underlying common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Weighted average risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Weighted average risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised", "verboseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares, Cancelled or forfeited", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Cancelled or forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares, Granted", "verboseLabel": "Number of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Ending balance, Aggregate Intrinsic Value", "periodStartLabel": "Beginning balance, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r340", "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance, Weighted-Average Exercise Price", "periodStartLabel": "Beginning balance, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Shares, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r331", "r336" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r333", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of shares subject to vest for additional stock-based compensation recognized" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Award expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r352", "r366" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfFairValueAssumptionsOfStockOptionAwardsEstimatedOnGrantDateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Share based compensation arrangement by Share based payment award purchase price of fair market value Common Stock Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share", "verboseLabel": "Redemption price per public warrant" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r101", "r104", "r129", "r130", "r131", "r134", "r136", "r144", "r145", "r146", "r189", "r225", "r229", "r230", "r231", "r234", "r235", "r281", "r282", "r286", "r290", "r297", "r425", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r55", "r64", "r65", "r66", "r111", "r112", "r113", "r115", "r122", "r125", "r143", "r190", "r297", "r302", "r362", "r363", "r364", "r379", "r380", "r409", "r427", "r428", "r429", "r430", "r431", "r432", "r536", "r537", "r538", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CoverPage", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r111", "r112", "r113", "r143", "r491" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingencies", "http://greenlightbiosciences.com/20220331/taxonomy/role/Debt", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombination1", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1", "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurements", "http://greenlightbiosciences.com/20220331/taxonomy/role/IncomeTaxes", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreement", "http://greenlightbiosciences.com/20220331/taxonomy/role/LicenseAgreementAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShare", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareTables", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r25", "r26", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Business Combination transaction, net of transaction costs of $26.7 million (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r255", "r297", "r298", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible notes (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Other (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r297", "r302" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock awards (in Shares)", "verboseLabel": "Restricted stock awards granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r297", "r302", "r342" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Shares, Exercised", "terseLabel": "Number of share options exercised during the current period", "verboseLabel": "Exercise of common stock options (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r55", "r297", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Business Combination transaction, net of transaction costs of $26.7 million" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r297", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r25", "r26", "r297", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r55", "r297", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r30", "r31", "r104", "r183", "r189", "r425", "r454" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r102", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r433", "r456" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r455", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH-FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r15", "r276" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r52", "r104", "r189", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Temporary equity Liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r15", "r276" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary equity, par or stated value per share", "verboseLabel": "Temporary equity par or stated value per share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Redeemable convertible preferred stock authorized", "terseLabel": "Convertible preferred stock authorized", "verboseLabel": "Temporary equity shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Redeemable convertible preferred stock issued", "terseLabel": "Convertible preferred stock issued", "verboseLabel": "Temporary equity shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Redeemable convertible preferred stock outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)", "terseLabel": "Convertible preferred stock outstanding", "verboseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquitySummaryOfLegacyRedeemableConvertiblePreferredStockAuthorizedIssuedAndOutstandingParentheticalDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r15", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "verboseLabel": "Summary of Legacy Redeemable Convertible Preferred Stock Authorized, Issued, and Outstanding" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r263", "r295", "r407", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/CommitmentsAndContingenciesDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r89" ], "calculation": { "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r147", "r148", "r150", "r151", "r152", "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants", "verboseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DebtAdditionalInformationDetail", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheExcludedPotentialCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Expiration Date", "verboseLabel": "Expiration Date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfCommonStockWarrantClassifiedDetails" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants, Measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants, Expected term (in years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsSummaryOfEstimatedFairValueOfTheWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Fair value warrants reclassified to equity" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average common stock outstanding-basic and diluted", "verboseLabel": "Weighted-average common stock outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://greenlightbiosciences.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationScheduleOfRestatementEarningsPerShareBasicAndDilutedDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/NetLossPerShareSummaryOfTheComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://greenlightbiosciences.com/20220331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498357-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 2)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45014-112735" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "605", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=123376971&loc=d3e50159-110409" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "605", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=123376971&loc=d3e50174-110409" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "605", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=123376971&loc=d3e50180-110409" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "605", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=123376971&loc=d3e50187-110409" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r561": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r563": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r564": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r565": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r572": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r573": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" }